Streck, Inc. Ms. Deborah Kipp Regulatory Affairs Manager 7002 South 109th Street La Vista, NE 68128

Re: K160588

Trade/Device Name: XN CHECK BF™   
Regulation Number: 21 CFR 864.8625   
Regulation Name: Hematology quality control mixture   
Regulatory Class: Class II   
Product Code: JPK   
Dated: October 17, 2016   
Received: October 18, 2016

Dear Ms. Kipp:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of

medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800)638-2041 or (301)796-7100 or at its Internet addresshttp://www.fda.gov/MedicalDevices/ResourcesforYou /Industry/default.htm. Also, please note the regulation entitled, sMisbranding by reference to premarket notifications (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov /MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/ Industry/default.htm.

# Sincerely, Leonthena R. Carrington -S

Leonthena R. Carrington, MS, MBA, MT(ASCP) Director   
Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health   
Center for Devices and Radiological Health

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden tie o hollectionforationetiateaveragehours psponse,nclud time to review instructions, search existing data sources, gatherand maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# 510(k) Summary

# 510(k) Submitter:

Streck 7002 South $1 0 9 ^ { \mathfrak { t h } }$ Street La Vista, NE 68128

Official Correspondent:   
Address:   
Phone:   
Fax:   
Date Prepared:

Deborah Kipp, Regulatory Affairs Manager   
7002 South $\dot { 1 } 0 9 ^ { \mathfrak { t h } }$ Street; La Vista, NE 68128   
402-537-5215   
402-537-5317   
Revised: October 14, 2016

# Names

Trade Name: Common Name: Classification Name: Product Code: Panel:

XN CHECK™ BF   
Assayed Hematology Control   
Hematology quality control mixture (864.8625)   
JPK   
Hematology

# Predicate Device:

XN CHECK™ BF (K141957)

# Intended Use:

XN CHECK BF is used for control and calibration verification of Sysmex XN series (XN-10, XN-11, XN-20, XN-21, XN-L) analyzers. It is not, however, intended for actual calibration of these analyzers. Assayed parameters include:

WBC-BF $( 1 0 ^ { 3 } / \mu \ L )$ , RBC-BF $( 1 0 ^ { 6 } / \mu \ L )$ , MN# $( 1 0 ^ { 3 } / \mu \ L )$ , PMN# $( 1 0 ^ { 3 } / \mu \ L )$ , $M N \%$ , $P M N \%$ , TC-BF# $( 1 0 ^ { 3 } / \mu \ L )$

# Description:

XN CHECK™ BF is an in-vitro diagnostic, two level, hematology control that contains the following: stabilized red blood cell component(s) and stabilized white blood cell component(s) in a preservative medium. The product is packaged in polypropylene plastic vials with screw caps with a $_ { 3 \mathrm { ~ m } }$ fill. The vials will be packaged in (4) welled vacuum formed clamshell container with the Instructions for Use (IFU) / assay sheet. Product storage conditions are $2 \cdot 8 ^ { \circ } \mathrm { ~ C ~ }$ .

Comparison to Predicate Device:   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>XN-CHECK BF (K141957) - PredicateDevice</td><td rowspan=1 colspan=1>XN CHECK T BF - Candidate Device</td><td rowspan=1 colspan=1>Same or Differences</td></tr><tr><td rowspan=1 colspan=1>IntendedUseStatement</td><td rowspan=1 colspan=1>XN CHECK BF is used for control andcalibration verification of Sysmex XNseries (XN-10, XN-11, XN-20, XN-21)analyzers. It is not, however, intendedfor actual calibration of these analyzers.Assayed parameters include:WBC-BF (103/μl), RBC-BF (10%/ μl), MN#(103/μl), PMN# (103/µl), MN% (%),PMN% (%), TC-BF# (103/μl)</td><td rowspan=1 colspan=1>XN CHECK BF is used for control andcalibration verification of Sysmex XN series(XN-10, XN-11, XN-20, XN-21, XN-L)analyzers. It is not, however, intended foractual calibration of these analyzers.Assayed parameters include:WBC-BF (103/μL), RBC-BF (106/μL), MN#(103/μL), PMN# (103/μL), MN%,PMN%, TC-BF# (103/μL)</td><td rowspan=1 colspan=1>Addition of XN-L Analyzer</td></tr><tr><td rowspan=1 colspan=1>Open VialStability</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>30 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Closed VialStability</td><td rowspan=1 colspan=1>84 days</td><td rowspan=1 colspan=1>84 days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reagents</td><td rowspan=1 colspan=1>XN CHECK BF contains the following:stabilized red blood cell component(s)and stabilized white blood cellcomponent(s) in a preservative medium.</td><td rowspan=1 colspan=1>XN CHECK BF contains the following:stabilized red blood cell component(s) andstabilized white blood cell component(s) in apreservative medium.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>StorageConditions</td><td rowspan=1 colspan=1>2-8</td><td rowspan=1 colspan=1>2-8</td><td rowspan=1 colspan=1>Same</td></tr></table>

# Discussion of Tests and Test Results:

To substantiate the product performance claims for XN CHECK BF, Streck collected product performance data for the following studies: Multi-Site Precision Study, Single-Site Precision Study, Open-Vial Stability and Closed-Vial Stability. The resultant data set established that XN CHECK BF is safe and effective for its intended use and that the product is stable for the entire product dating. The product fulfills its intended use as instructed in the Instructions for Use.

# Conclusions Drawn From Tests:

Study results show XN CHECK BF to be consistently reproducible, substantially equivalent to the predicate products, and stable for the entire product dating. XN CHECK BF is a safe and effective product, which fulfills its intended use when used as instructed in the Instructions for Use.